BIOCANCELL THERAPEUTICS INC. Research and Development Expense
BIOCANCELL THERAPEUTICS INC. reported Research and Development Expense of $923.00 thousand for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2012-05-10
- BIOCANCELL THERAPEUTICS INC. research and development expense for the quarter ending 2012-03-31 was $923.00K, a 33.77% increase year-over-year.
- BIOCANCELL THERAPEUTICS INC. research and development expense for the quarter ending 2011-12-31 was $1.28M, a 56.33% increase year-over-year.
- BIOCANCELL THERAPEUTICS INC. research and development expense for the quarter ending 2011-09-30 was $991.00K, a 164.97% increase year-over-year.
- BIOCANCELL THERAPEUTICS INC. research and development expense for the quarter ending 2011-06-30 was $963.00K, a 101.89% increase year-over-year.
- BIOCANCELL THERAPEUTICS INC. research and development expense for fiscal 2011 was $3.93M, a 78.02% increase from fiscal 2010.
- BIOCANCELL THERAPEUTICS INC. research and development expense for fiscal 2010 was $2.21M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 81 month | Research and Development Expense 84 month | Research and Development Expense 87 month | Research and Development Expense 90 month |
|---|---|---|---|---|---|---|---|---|
| 2012-03-31 | $923.00K 10-Q · filed 2012-05-10 | $2.21M derived: sum of 2 quarters · filed 2012-05-10 | $3.20M derived: sum of 3 quarters · filed 2012-05-10 | $4.16M derived: sum of 4 quarters · filed 2012-05-10 | $18.33M 10-Q · filed 2012-05-10 | |||
| 2011-12-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-30 | $2.28M derived: sum of 2 quarters · filed 2012-03-30 | $3.24M derived: sum of 3 quarters · filed 2012-03-30 | $3.93M 10-K · filed 2012-03-30 | $17.41M 10-K · filed 2012-03-30 | |||
| 2011-09-30 | $991.00K 10-Q · filed 2011-11-07 | $1.95M derived: sum of 2 quarters · filed 2011-11-07 | $2.64M 10-Q · filed 2011-11-07 | $3.47M derived: sum of 4 quarters · filed 2012-05-10 | $16.12M 10-Q · filed 2011-11-07 | |||
| 2011-06-30 | $963.00K 10-Q/A · filed 2011-08-30 | $1.65M 10-Q/A · filed 2011-08-30 | $2.48M derived: sum of 3 quarters · filed 2012-05-10 | $2.85M derived: sum of 4 quarters · filed 2012-05-10 | $15.13M 10-Q/A · filed 2011-08-30 | |||
| 2011-03-31 | $690.00K 10-Q · filed 2012-05-10 | $1.51M derived: sum of 2 quarters · filed 2012-05-10 | $1.89M derived: sum of 3 quarters · filed 2012-05-10 | $2.36M derived: sum of 4 quarters · filed 2012-05-10 | ||||
| 2010-12-31 | $822.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-30 | $1.20M derived: sum of 2 quarters · filed 2012-03-30 | $1.67M derived: sum of 3 quarters · filed 2012-03-30 | $2.21M 10-K · filed 2012-03-30 | ||||
| 2010-09-30 | $374.00K 10-Q · filed 2011-11-07 | $851.00K derived: sum of 2 quarters · filed 2011-11-07 | $1.39M 10-Q · filed 2011-11-07 | |||||
| 2010-06-30 | $477.00K 10-Q/A · filed 2011-08-30 | $1.01M 10-Q/A · filed 2011-08-30 |